A New Peptide Carrier That Delivers Enzymes to Lysosomes for Treating Storage Diseases
A fusion peptide combining polylysine and polyhistidine successfully delivers replacement enzymes to lysosomes, restoring normal cell growth in lysosomal storage disease cells.
Quick Facts
What This Study Found
The K10H16 fusion peptide delivers functional enzymes to intracellular lysosomes via electrostatic complexation, restoring normal cell growth in lysosomal storage disease cells.
Key Numbers
K10H16 (26 AA); lysosomal targeting confirmed; GLA delivered; LSD cell proliferation restored; simple electrostatic mixing
How They Did This
Peptide synthesis, fluorescent protein delivery tracking, alpha-galactosidase A delivery to LSD cells, and cell proliferation assays.
Why This Research Matters
Lysosomal storage diseases currently require enzyme replacement therapy with limited cell penetration. A peptide carrier delivering enzymes directly to lysosomes could dramatically improve treatment efficacy.
The Bigger Picture
This approach could transform enzyme replacement therapy for lysosomal storage diseases by solving the fundamental challenge of getting replacement enzymes inside cells to the organelle where they're needed.
What This Study Doesn't Tell Us
In vitro proof-of-concept only. No in vivo data on peptide stability, biodistribution, or therapeutic efficacy.
Questions This Raises
- ?Does K10H16 work for delivering enzymes in animal models of lysosomal storage diseases?
- ?Can this approach be adapted for other lysosomal enzyme deficiencies beyond Fabry disease?
- ?How does efficiency compare to existing enzyme replacement approaches?
Trust & Context
- Key Stat:
- Restored growth LSD cells treated with K10H16-delivered enzyme resumed normal proliferation rates
- Evidence Grade:
- In vitro proof-of-concept demonstrating peptide-mediated enzyme delivery to lysosomes. Promising but requires in vivo validation.
- Study Age:
- Published in 2020. The concept of CPP-mediated enzyme delivery continues to be actively explored.
- Original Title:
- A polylysine-polyhistidine fusion peptide for lysosome-targeted protein delivery.
- Published In:
- Biochemical and biophysical research communications, 533(4), 905-912 (2020)
- Authors:
- Iwasaki, Takashi(2), Murakami, Nodoka, Kawano, Tsuyoshi(2)
- Database ID:
- RPEP-04879
Evidence Hierarchy
Frequently Asked Questions
What are lysosomal storage diseases?
Lysosomal storage diseases are genetic conditions where cells lack specific enzymes needed to break down waste products inside lysosomes (cellular recycling centers). Without these enzymes, waste accumulates and causes cell damage. There are over 50 types, including Fabry disease.
How does this peptide deliver enzymes into cells?
The K10H16 peptide has two functional parts: a positively charged polylysine section that binds to negatively charged enzymes, and a polyhistidine section that enables cell entry. Once inside the cell, the peptide-enzyme complex is directed to lysosomes where the enzyme is needed.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04879APA
Iwasaki, Takashi; Murakami, Nodoka; Kawano, Tsuyoshi. (2020). A polylysine-polyhistidine fusion peptide for lysosome-targeted protein delivery.. Biochemical and biophysical research communications, 533(4), 905-912. https://doi.org/10.1016/j.bbrc.2020.09.087
MLA
Iwasaki, Takashi, et al. "A polylysine-polyhistidine fusion peptide for lysosome-targeted protein delivery.." Biochemical and biophysical research communications, 2020. https://doi.org/10.1016/j.bbrc.2020.09.087
RethinkPeptides
RethinkPeptides Research Database. "A polylysine-polyhistidine fusion peptide for lysosome-targe..." RPEP-04879. Retrieved from https://rethinkpeptides.com/research/iwasaki-2020-a-polylysinepolyhistidine-fusion-peptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.